CTOs on the Move

Galecto

www.galecto.com

 
Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Beta Bionics

Beta Bionics is proud to be a Massachusetts public benefit corporation.

Employers Drug Program Management

Employers Drug Program Management is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Outlook Therapeutics

Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.

Ventana Clinical Research Corp

Ventana Clinical Research Corp is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LA Habilitation House

LA Habilitation House is a Long Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.